326 related articles for article (PubMed ID: 10674778)
21. Reduction of respiratory syncytial virus hospitalization among premature infants and infants with bronchopulmonary dysplasia using respiratory syncytial virus immune globulin prophylaxis. The PREVENT Study Group.
Pediatrics; 1997 Jan; 99(1):93-9. PubMed ID: 8989345
[TBL] [Abstract][Full Text] [Related]
22. Hospitalisation for RSV infection in ex-preterm infants-implications for use of RSV immune globulin.
Thomas M; Bedford-Russell A; Sharland M
Arch Dis Child; 2000 Aug; 83(2):122-7. PubMed ID: 10906017
[TBL] [Abstract][Full Text] [Related]
23. Safety, tolerance and pharmacokinetics of a humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia. MEDI-493 Study Group.
Subramanian KN; Weisman LE; Rhodes T; Ariagno R; Sánchez PJ; Steichen J; Givner LB; Jennings TL; Top FH; Carlin D; Connor E
Pediatr Infect Dis J; 1998 Feb; 17(2):110-5. PubMed ID: 9493805
[TBL] [Abstract][Full Text] [Related]
24. Role of antibody and use of respiratory syncytial virus (RSV) immune globulin to prevent severe RSV disease in high-risk children.
Groothuis JR
J Pediatr; 1994 May; 124(5 Pt 2):S28-32. PubMed ID: 8169755
[TBL] [Abstract][Full Text] [Related]
25. Monoclonal antibody for reducing the risk of respiratory syncytial virus infection in children.
Andabaka T; Nickerson JW; Rojas-Reyes MX; Rueda JD; Bacic Vrca V; Barsic B
Cochrane Database Syst Rev; 2013 Apr; (4):CD006602. PubMed ID: 23633336
[TBL] [Abstract][Full Text] [Related]
26. Respiratory syncytial virus infection: clinical features, management, and prophylaxis.
Greenough A
Curr Opin Pulm Med; 2002 May; 8(3):214-7. PubMed ID: 11981311
[TBL] [Abstract][Full Text] [Related]
27. RSV immune globulin prophylaxis: is an ounce of prevention worth a pound of cure?
Moler FW
Pediatrics; 1999 Sep; 104(3 Pt 1):559-60. PubMed ID: 10469785
[No Abstract] [Full Text] [Related]
28. Restrictive Palivizumab Use Does Not Lead to Increased Morbidity and Mortality in Pediatric Hematopoietic Stem Cell Transplantation Patients.
Teusink-Cross A; Davies SM; Danziger-Isakov L; El-Bietar J; Grimley MS
Biol Blood Marrow Transplant; 2016 Oct; 22(10):1904-1906. PubMed ID: 27422147
[TBL] [Abstract][Full Text] [Related]
29. Efficacy and optimization of palivizumab injection regimens against respiratory syncytial virus infection.
Gutfraind A; Galvani AP; Meyers LA
JAMA Pediatr; 2015 Apr; 169(4):341-8. PubMed ID: 25706618
[TBL] [Abstract][Full Text] [Related]
30. Prophylactic administration of respiratory syncytial virus immune globulin to high-risk infants and young children. The Respiratory Syncytial Virus Immune Globulin Study Group.
Groothuis JR; Simoes EA; Levin MJ; Hall CB; Long CE; Rodriguez WJ; Arrobio J; Meissner HC; Fulton DR; Welliver RC
N Engl J Med; 1993 Nov; 329(21):1524-30. PubMed ID: 8413475
[TBL] [Abstract][Full Text] [Related]
31. Respiratory syncytial virus immune globulin intravenous: indications for use. American Academy of Pediatrics Committee on Infectious Diseases, Committee on Fetus and Newborn.
Pediatrics; 1997 Apr; 99(4):645-50. PubMed ID: 9093323
[TBL] [Abstract][Full Text] [Related]
32. Prevention of respiratory syncytial virus infection with palivizumab.
Thomas M; Bedford-Russell A; Sharland M
Monaldi Arch Chest Dis; 2000 Aug; 55(4):333-8. PubMed ID: 11057088
[TBL] [Abstract][Full Text] [Related]
33. Palivizumab for prophylaxis against respiratory syncytial virus infection in children with cystic fibrosis.
Robinson KA; Odelola OA; Saldanha I; McKoy N
Cochrane Database Syst Rev; 2010 Feb; (2):CD007743. PubMed ID: 20166098
[TBL] [Abstract][Full Text] [Related]
34. Palivizumab: a review of its use as prophylaxis for serious respiratory syncytial virus infection.
Fenton C; Scott LJ; Plosker GL
Paediatr Drugs; 2004; 6(3):177-97. PubMed ID: 15170364
[TBL] [Abstract][Full Text] [Related]
35. Respiratory syncytial virus and premature infants born at 32 weeks' gestation or earlier: hospitalization and economic implications of prophylaxis.
Stevens TP; Sinkin RA; Hall CB; Maniscalco WM; McConnochie KM
Arch Pediatr Adolesc Med; 2000 Jan; 154(1):55-61. PubMed ID: 10632251
[TBL] [Abstract][Full Text] [Related]
36. Respiratory syncytial virus immune globulin for prophylaxis against respiratory syncytial virus disease in infants and children with congenital heart disease. The Cardiac Study Group.
Simoes EA; Sondheimer HM; Top FH; Meissner HC; Welliver RC; Kramer AA; Groothuis JR
J Pediatr; 1998 Oct; 133(4):492-9. PubMed ID: 9787686
[TBL] [Abstract][Full Text] [Related]
37. A review of palivizumab and emerging therapies for respiratory syncytial virus.
Shadman KA; Wald ER
Expert Opin Biol Ther; 2011 Nov; 11(11):1455-67. PubMed ID: 21831008
[TBL] [Abstract][Full Text] [Related]
38. Cost effectiveness of palivizumab for respiratory syncytial virus prophylaxis in high-risk children: a UK analysis.
Nuijten MJ; Wittenberg W; Lebmeier M
Pharmacoeconomics; 2007; 25(1):55-71. PubMed ID: 17192118
[TBL] [Abstract][Full Text] [Related]
39. Respiratory syncytial virus immune globulin intravenous.
Wandstrat TL
Ann Pharmacother; 1997 Jan; 31(1):83-8. PubMed ID: 8997472
[TBL] [Abstract][Full Text] [Related]
40. Palivizumab.
Scott LJ; Lamb HM
Drugs; 1999 Aug; 58(2):305-11; discussion 312-3. PubMed ID: 10473022
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
